ReviewInternational journal of molecular sciences2026
Biomarkers and Early Mechanisms of Sarcopenia: Central Roles of Mitochondrial Dysfunction, Inflammaging, Cellular Senescence, and Neuromuscular Degeneration.
Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia is a progressive age-related skeletal muscle disorder characterized by the loss of muscle mass, strength, and physical performance, leading to frailty, disability, and increased mortality. Although its clinical consequences are well recognized, the underlying biological mechanisms remain incompletely understood, limiting the development of early diagnostic strategies and targeted therapies. Increasing evidence indicates that sarcopenia results from complex interactions among mitochondrial dysfunction, chronic low-grade inflammation (inflammaging), cellular senescence, neuromuscular junction degeneration, and anabolic resistance. The present review critically summarizes the current evidence on the principal circulating and molecular biomarkers associated with these interconnected mechanisms. Mitochondrial dysfunction appears to represent an early upstream event that promotes excessive reactive oxygen species production, defective mitophagy, inflammatory activation, and cellular senescence. Chronic inflammation, mediated primarily through IL-6 and TNF-α, further accelerates muscle catabolism and regenerative failure, whereas senescence-associated pathways impair satellite cell function and muscle repair. Neuromuscular degeneration and anabolic resistance further contribute to progressive muscle atrophy and functional decline. Among the candidate biomarkers, GDF-15, FGF-21, IL-6, TNF-α, CAF22, p16INK4a, p21/CDKN1A, IGF-1, and myostatin appear particularly promising for characterizing the biological heterogeneity of sarcopenia. However, no single biomarker currently demonstrates sufficient diagnostic accuracy for routine clinical use. Instead, integrated multi-biomarker approaches combining mitochondrial, inflammatory, senescence-associated, neuromuscular, and anabolic markers may improve early diagnosis, risk stratification, and personalized therapeutic strategies. Future prospective longitudinal studies are required to validate these biomarkers and facilitate their translation into clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.